RTK Inhibitors in Melanoma: From Bench to Bedside

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 30

PMID 33918490

Citations 24

Authors

Malak Sabbah

Ahmad Najem

Mohammad Krayem

Ahmad Awada

Fabrice Journe

Ghanem E Ghanem

Affiliations

Soon will be listed here.

Abstract

MAPK (mitogen activated protein kinase) and PI3K/AKT (Phosphatidylinositol-3-Kinase and Protein Kinase B) pathways play a key role in melanoma progression and metastasis that are regulated by receptor tyrosine kinases (RTKs). Although RTKs are mutated in a small percentage of melanomas, several receptors were found up regulated/altered in various stages of melanoma initiation, progression, or metastasis. Targeting RTKs remains a significant challenge in melanoma, due to their variable expression across different melanoma stages of progression and among melanoma subtypes that consequently affect response to treatment and disease progression. In this review, we discuss in details the activation mechanism of several key RTKs: type III: c-KIT (mast/stem cell growth factor receptor); type I: EGFR (Epidermal growth factor receptor); type VIII: HGFR (hepatocyte growth factor receptor); type V: VEGFR (Vascular endothelial growth factor), structure variants, the function of their structural domains, and their alteration and its association with melanoma initiation and progression. Furthermore, several RTK inhibitors targeting the same receptor were tested alone or in combination with other therapies, yielding variable responses among different melanoma groups. Here, we classified RTK inhibitors by families and summarized all tested drugs in melanoma indicating the rationale behind the use of these drugs in each melanoma subgroups from preclinical studies to clinical trials with a specific focus on their purpose of treatment, resulted effect, and outcomes.

Citing Articles

Design and synthesis of antiproliferative 2-oxoindolin-3-ylidenes incorporating urea function with potential VEGFR-2 inhibitory properties.

Aboshouk D, Youssef M, Panda S, Kariuki B, Bekheit M, Hamed A Sci Rep. 2025; 15(1):618.

PMID: 39753596 PMC: 11699130. DOI: 10.1038/s41598-024-82005-6.

Oncogenic RTKs sensitize cancer cells to ferroptosis via c-Myc mediated upregulation of ACSL4.

Sun N, Wang J, Qin J, Ma S, Luan J, Hou G Cell Death Dis. 2024; 15(11):861.

PMID: 39604370 PMC: 11603294. DOI: 10.1038/s41419-024-07254-9.

Expression of variant isoforms of the tyrosine kinase SYK differentially regulates cervical cancer progression through PI3K/AKT pathway.

Lin B, Wang Q, Wang X, Wei H, Nie X, Li L Sci Rep. 2024; 14(1):29080.

PMID: 39580521 PMC: 11585633. DOI: 10.1038/s41598-024-80579-9.

Design and Synthesis of New Dihydropyrimidine Derivatives with a Cytotoxic Effect as Dual EGFR/VEGFR-2 Inhibitors.

Al-Wahaibi L, Elshamsy A, Ali T, Youssif B, Brase S, Abdel-Aziz M ACS Omega. 2024; 9(32):34358-34369.

PMID: 39157105 PMC: 11325413. DOI: 10.1021/acsomega.4c01361.

Development of Personalized Strategies for Precisely Battling Malignant Melanoma.

Isaak A, Clements G, Buenaventura R, Merlino G, Yu Y Int J Mol Sci. 2024; 25(9).

PMID: 38732242 PMC: 11084485. DOI: 10.3390/ijms25095023.

References

Hu-Lowe D, Zou H, Grazzini M, Hallin M, Wickman G, Amundson K . Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008; 14(22):7272-83. DOI: 10.1158/1078-0432.CCR-08-0652. View

Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M . Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 1996; 7(2):213-21. View

Potti A, Hille R, Koch M . Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. J Carcinog. 2003; 2(1):8. PMC: 280698. DOI: 10.1186/1477-3163-2-8. View

Luis Manzano J, Layos L, Buges C, de Los Llanos Gil M, Vila L, Martinez-Balibrea E . Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016; 4(12):237. PMC: 4930524. DOI: 10.21037/atm.2016.06.07. View

Dufies M, Jacquel A, Robert G, Cluzeau T, Puissant A, Fenouille N . Mechanism of action of the multikinase inhibitor Foretinib. Cell Cycle. 2011; 10(23):4138-48. DOI: 10.4161/cc.10.23.18323. View

Adams T, Epa V, Garrett T, Ward C . Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000; 57(7):1050-93. PMC: 11146944. DOI: 10.1007/PL00000744. View

Fleishman S, Schlessinger J, Ben-Tal N . A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002; 99(25):15937-40. PMC: 138543. DOI: 10.1073/pnas.252640799. View

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

Minor D, Kashani-Sabet M, Garrido M, ODay S, Hamid O, Bastian B . Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012; 18(5):1457-63. DOI: 10.1158/1078-0432.CCR-11-1987. View

10.

Cohen M, Johnson J, Chen Y, Sridhara R, Pazdur R . FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005; 10(7):461-6. DOI: 10.1634/theoncologist.10-7-461. View

11.

Pollack B . EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?. Oncoimmunology. 2012; 1(1):71-74. PMC: 3376950. DOI: 10.4161/onci.1.1.18073. View

12.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

13.

Kong-Beltran M, Stamos J, Wickramasinghe D . The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004; 6(1):75-84. DOI: 10.1016/j.ccr.2004.06.013. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Corso S, Comoglio P, Giordano S . Cancer therapy: can the challenge be MET?. Trends Mol Med. 2005; 11(6):284-92. DOI: 10.1016/j.molmed.2005.04.005. View

16.

Adjei A, Schwartz B, Garmey E . Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist. 2011; 16(6):788-99. PMC: 3228218. DOI: 10.1634/theoncologist.2010-0380. View

17.

Munoz-Couselo E, Adelantado E, Ortiz C, Soberino Garcia J, Perez-Garcia J . -mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017; 10:3941-3947. PMC: 5558581. DOI: 10.2147/OTT.S117121. View

18.

Imbulgoda A, Heng D, Kollmannsberger C . Sunitinib in the treatment of advanced solid tumors. Recent Results Cancer Res. 2014; 201:165-84. DOI: 10.1007/978-3-642-54490-3_9. View

19.

Jiang X, Zhou J, Yuen N, Corless C, Heinrich M, Fletcher J . Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008; 14(23):7726-32. DOI: 10.1158/1078-0432.CCR-08-1144. View

20.

Landau M, Fleishman S, Ben-Tal N . A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure. 2004; 12(12):2265-75. DOI: 10.1016/j.str.2004.10.006. View